P3.01-37 Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients With Wild-Type EGFR: TORG 1320
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1597
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV